| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.082 | 0.1 |
| mRNA | QL-XII-61 | GDSC1000 | pan-cancer | AAC | 0.078 | 0.1 |
| mRNA | AR-42 | GDSC1000 | pan-cancer | AAC | -0.048 | 0.1 |
| mRNA | BCL-LZH-4 | CTRPv2 | pan-cancer | AAC | 0.09 | 0.1 |
| mRNA | CD-1530 | CTRPv2 | pan-cancer | AAC | -0.064 | 0.1 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | -0.084 | 0.1 |
| mRNA | BRD-K35604418 | CTRPv2 | pan-cancer | AAC | 0.062 | 0.1 |
| mRNA | GSK2126458 | GDSC1000 | pan-cancer | AAC | 0.05 | 0.1 |
| mRNA | MS-275 | CTRPv2 | pan-cancer | AAC | -0.054 | 0.1 |
| mRNA | carboplatin:etoposide (40:17 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.049 | 0.1 |